These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8847018)

  • 1. Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy.
    Boehme MW; Schmidt-Gayk H; Bihl H; Eisenhut M; Herfarth CH; Kommere B; Raeth U
    Hepatogastroenterology; 1995; 42(6):1053-61. PubMed ID: 8847018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
    Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency.
    Woltering EA; Hilton RS; Zolfoghary CM; Thomson J; Zietz S; Go VL; Vinik AI; Vinik E; O'Dorisio TM; Mamikunian G
    Pancreas; 2006 Oct; 33(3):250-4. PubMed ID: 17003646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromogranin A as a determinant of midgut carcinoid tumour volume.
    Kölby L; Bernhardt P; Swärd C; Johanson V; Ahlman H; Forssell-Aronsson E; Stridsberg M; Wängberg B; Nilsson O
    Regul Pept; 2004 Aug; 120(1-3):269-73. PubMed ID: 15177946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors.
    Dakin GF; Warner RR; Pomp A; Salky B; Inabnet WB
    J Surg Oncol; 2006 Apr; 93(5):368-72. PubMed ID: 16550587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995.
    Wiedenmann B; Räth U; Rädsch R; Becker F; Kommerell B
    Klin Wochenschr; 1988 Jan; 66(2):75-7. PubMed ID: 2894481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.
    Kölby L; Persson G; Franzén S; Ahrén B
    Br J Surg; 2003 Jun; 90(6):687-93. PubMed ID: 12808615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
    Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
    Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
    Janson ET; Oberg K
    Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sandostatin on plasma chromogranin-A levels in neuroendocrine tumors.
    Moattari AR; Deftos LJ; Vinik AI
    J Clin Endocrinol Metab; 1989 Oct; 69(4):902-5. PubMed ID: 2778040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
    Khuroo MS; Khuroo MS; Khuroo NS
    J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
    Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
    Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Carcinoid tumors].
    Tóth M; Prónai L; Németh AM; Tulassay Z
    Orv Hetil; 2002 May; 143(19 Suppl):1087-92. PubMed ID: 12063867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors].
    Bläker M; de Weerth A
    Z Gastroenterol; 2006 Sep; 44(9):1003-4. PubMed ID: 16981075
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study.
    Thomas D; Tsolakis AV; Grozinsky-Glasberg S; Fraenkel M; Alexandraki K; Sougioultzis S; Gross DJ; Kaltsas G
    Eur J Endocrinol; 2013 Feb; 168(2):185-93. PubMed ID: 23132699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosing, treating and managing carcinoid tumours.
    Burgess A
    Nurs Times; 2005 Jul 19-25; 101(29):32-4. PubMed ID: 16052941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tailored intermittent therapy of carcinoid.
    Kinová S; Duris I; Kratochvíl'ová E; Kovácová E; Koren M
    Hepatogastroenterology; 2007 Sep; 54(78):1716-9. PubMed ID: 18019702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete histological regression of metastatic carcinoid tumour after treatment with octreotide.
    Imtiaz KE; Monteith P; Khaleeli A
    Clin Endocrinol (Oxf); 2000 Dec; 53(6):755-8. PubMed ID: 11155099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Carcinoid tumors].
    Pregun I; Bodoky G; Rácz K; Tulassay Z
    Orv Hetil; 2010 Nov; 151(46):1885-94. PubMed ID: 21044939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide.
    Joensuu H; Kätkä K; Kujari H
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):184-5. PubMed ID: 1371898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.